OSELTAMAVIR PHOSPHATE (oseltamavir phosphate) Nursing Considerations

What is the generic name?

OSELTAMAVIR PHOSPHATE

What is the Trade Name for OSELTAMAVIR PHOSPHATE?

oseltamavir phosphate

What are the Indications for OSELTAMAVIR PHOSPHATE?

• 1 INDICATIONS & USAGE Oseltamivir phosphate capsules USP, is an influenza neuraminidase inhibitor (NAI) indicated for: ‚Ä¢ Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) ‚Ä¢ Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use: ‚Ä¢ Not a substitute for annual influenza vaccination. ( 1.3 ) ‚Ä¢ Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) ‚Ä¢ Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 ) 1.1 Treatment of Influenza Oseltamivir phosphate capsule is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. 1.2 Prophylaxis of Influenza Oseltamivir phosphate capsule is indicated for the prophylaxis of influenza A and B in patients 1 year and older. 1.3 Limitations of Use ‚Ä¢ Oseltamivir phosphate capsule is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. ‚Ä¢ Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use Oseltamivir phosphate capsules [ see Microbiology ( 12.4 ) ]. ‚Ä¢ Oseltamivir phosphate capsule is not recommended for patients with end-stage renal disease not undergoing dialysis [ see Dosage and Administration ( 2.4 ) and Use in Specific Populations ( 8.6 ) ].

References: https://open.fda.gov/